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The transcription factor p63 is expressed as at least six different isoforms, of which two have been assigned critical biological
roles within ectodermal development and skin stem cell biology on the one hand and supervision of the genetic stability of
oocytes on the other hand. These two isoforms contain a C-terminal inhibitory domain that negatively regulates their
transcriptional activity. This inhibitory domain contains two individual components: one that uses an internal binding
mechanism to interact with and mask the transactivation domain and one that is based on sumoylation. We have carried out an
extensive alanine scanning study to identify critical regions within the inhibitory domain. These experiments show that a stretch
of B13 amino acids is crucial for the binding function. Further, investigation of transcriptional activity and the intracellular level
of mutants that cannot be sumoylated suggests that sumoylation reduces the concentration of p63. We therefore propose that
the inhibitory function of the C-terminal domain is in part due to direct inhibition of the transcriptional activity of the protein and
in part due to indirect inhibition by controlling the concentration of p63.
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The transcription factor p63 shows high sequence homology
to the tumor suppressor p53.
1–4 Although the potential role of
p63 in tumor suppression is still debated,
5–8 it has been
assigned crucial roles in epithelial stem cell biology and in
surveillance of the genetic stability of oocytes.
9–14 These two
distinct biological functions are executed by the two isoforms
of p63 that possess a non-truncated form of the C-terminus.
TAp63a, which represents the full gene product, is expressed
in oocytes,
12 while the DNp63a isoform, which lacks the
N-terminal transactivation domain, is highly expressed in the
basal layer of epithelial tissues.
9 The four additional isoforms
of p63, which have not been ascribed speciﬁc functions to
date, are created through the combination of the two different
N-termini (TA and DN) with additional C-terminal splice
variants consummating the six combinations: TAp63a,
TAp63b, TAp63g, DNp63a, DNp63b, and DNp63g.
2 The six
isoforms show very different transcriptional activities in cell
culture experiments.
2,15 Owing to the presence of the TA
domain, TAp63b and TAp63g are constitutively active on
prototypical p53 promoters such as p21, mdm2, and bax, but
TAp63a is rendered inactive by an auto-inhibitory sequence
located within the a C-terminus.
2,15,16 This same C-terminal
inhibitory element endows the DNp63 a isoform with a strong
dominant-negative ability against TAp63g.
2
In a previous study, we had mapped the auto-inhibitory
domain (transcriptional inhibitory domain (TID)) in TAp63a to
the last 70 amino acids.
15 Further biochemical analysis
suggested that the TID interacts with the N-terminal transac-
tivation domain, thus forming a closed and inactive conforma-
tion of the transcription factor. These experiments also
revealed that the TID contains two different subdomains,
both of which differentially contribute to the observed
inhibition. Whereas the 45 N-terminal amino acids of the TID
are involved in binding and masking of the TA domain, the 25
C-terminal amino acids do not contribute to binding, but are
responsible for B50% of the overall inhibitory effect of
the TID. Sequence analysis showed that this C-terminal
subdomain contains a classical sumoylation sequence and
sumoylation in the C-terminus was shown for both
TAp63a
17,18 and the highly homologous protein TAp73a.
19
To gain further insight into the different mechanisms of
auto-inhibition and of potential relief of auto-inhibition within
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The results presented here show that a stretch of B13 highly
conserved amino acids is responsible for the auto-inhibiting
intramolecular interaction. In addition, our results suggest that
sumoylation inhibits the transcriptional activity of TAp63a
indirectly by reducing its intracellular concentration.
Results
The TAp63a C-terminus contains two distinct inhibitory
elements. Using C-terminal deletion mutagenesis we had
previously shown that the intramolecular inhibition in TAp63a
can be disrupted by removing the last 35 amino acids.
15 The
aim of this study was to use site-directed mutagenesis
between the last helix of the SAM domain and the C-terminus
of TAp63a (amino acids 563–641) to identify amino acids that
are important for the inhibitory mechanism. In our previous
study, we had shown a correlation between the binding of
deletion mutants to an external TI domain in GST pulldown
assays and the transcriptional activity of these mutants on
the p21 promoter in SAOS2 cells.
15 Here we use the same
assays in combination with investigation of the intracellular
concentration to obtain a more detailed picture of the function
of the TI domain.
To identify crucial amino acids within the inhibitory domain,
we generated a library of 16 mutant TAp63a clones in which
three consecutive amino acids were simultaneously mutated
to alanine (Table 1, clones 1–17). The mutant clones will be
referenced according to the abbreviations listed in
Table 1; mutant clone 1, which corresponds to the triple
mutant W559A/K560A/G561A, will be referred to as
TAp63a
WKG4AAA. Once constructed, the library of mutants
was assayed for transcriptional activity on the p21 promoter
(Figure 1a).
An increase to 30–40% of the activity of the fully active
isoform TAp63g was observed for mutants between amino
acids F605 and R616 as well as for mutant TAp63a
QRI4AAA.
This last mutant affects the sumoylation site in p63 and it had
been shown that its removal increases the transcriptional
activity to 40–50% of TAp63g.
15,18 Previously reported pull-
down experiments had demonstrated that the last 25 amino
acids, including the sumoylation site, are not important for
binding of the TA domain but act independently.
15 Owing to
the increase in activity both by mutations in the region
605–616 and in the sumoylation site, a second library was
constructed by adding a K637L mutation to each clone that
removes the acceptor lysine of the sumoylation site
(Table 1, clones 18–34). In this second library the mutants
TAp63a
FTL4AAA and TAp63a
TIS4AAA, which previously in-
creased moderately, increased to an excess of 100% activity.
In addition, TAp63a
SFP4AAA and TAp63a
PPR4AAA showed a
signiﬁcantly increased activity. Outside of these clones, the
Table 1 Alanine scanning library covering from the end of the SAM domain to
the C-terminus of TAp63a
Clone Amino acids Abbreviation
1 W559A/K560A/G561A WKG4AAA
2 H565A/R566A/Q567A HRQ4AAA
3 D560A/F561A/S562A DFS4AAA
4 H576A/L577A/L578A HLL4AAA
5 S582A/G583A SG4AA
6 S588A/V589A/G590A SVG4AAA
7 S592A/E593A/T594A SET4AAA
8 G596A/E597A/R598A GER4AAA
9 I600A/D601 ID4AAA
10 F605A/T606A/L607A FTL4AAA
11 T610A/I611A/S612A TIS4AAA
12 S612A/F613A/P614A SFP4AAA
13 P614A/P615A/R616A PPR4AAA
14 E618A/W619A/N620A EWN4AAA
15 F624A/D625A/M626A FDM4AAA
16 S628A/R629A/R630A SRR4AAA
17 Q634A/R635A/I636A QRI4AAA
18 K637L K4L
19 W559A/K560A/G561A/K637L WKG4AAA/K4L
20 H565A/R566A/Q567A/K637L HRQ4AAA/K4L
21 D560A/F561A/S562A/K637L DFS4AAA/K4L
22 H576A/L577A/L578A/K637L HLL4AAA/K4L
23 S582A/G583A/K637L SG4AA/K4L
24 S588A/V589A/G590A/K637L SVG4AAA/K4L
25 S592A/E593A/T594A/K637L SET4AAA/K4L
26 G596A/E597A/R598A/K637L GER4AAA/K4L
27 I600A/D601/K637L ID4AAA/K4L
28 F605A/T606A/L607A/K637L FTL4AAA/K4L
29 T610A/I611A/S612A/K637L TIS4AAA/K4L
30 S612A/F613A/P614A/K637L SFP4AAA/K4L
31 P614A/P615A/R616A/K637L PPR4AAA/K4L
32 E618A/W619A/N620A/K637L EWN4AAA/K4L
33 F624A/D625A/M626A/K637L FDM4AAA/K4L
34 S628A/R629A/R630A/K637L SRR4AAA/K4L
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Figure 1 Investigation of the relative transcriptional activity of several triple-
alanine mutants of TAp63a in SAOS-2 cells on a p21 promoter. (a) Each
measurement was carried out in triplicate. The activity of the wild-type TAp63a and
TAp63g is shown in blue and green, respectively. The activity of TAp63 g is set to
100%.(b)Determinationoftheintracellularproteinlevelofthedifferentp63mutants
usinganN-terminalmyc-tag.ForstandardizationwesternblotsofGAPDHareused.
The transcriptional activity measured in (a) is normalized with the western blots to
eliminate the inﬂuence of the intracellular protein level. Only mutants in a stretch
between F605 and R616 show an increased activity
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Cell Death and Diseaseactivity of most of the remaining constructs bearing the K637L
mutation increased to approximately 30–40% of the activity
level of TAp63g, which is an effect attributed to the mutation in
the sumoylation site (Figure 2a), as a similar increase in
activity was also observed when K637L was the only mutation
in TAp63a.
Similar results can be obtained with mutant TAp63a forms
lacking a stretch of amino acids between Q402–T495 (called
QP domain owing to its high content of glutamines and
prolines, and which harbors a helix that interacts with the
oligomerizationdomain
20).AlthoughTAp63aDQPisevenless
active than TAp63a, removal of the sumoylation site leads to a
slight increase and mutation of F605/T606/L607 to AAA leads
to a strong increase in transcriptional activity, suggesting that
the entire QP domain is not necessary for the inhibitory
mechanism (Supplementary Figure S1).
An alignment of TAp63a proteins from diverse species
revealed several conserved amino acids in the C-terminus,
with the most signiﬁcant cluster spanning 10 amino acids.
With only slight exceptions, the amino acids traversed by the
two active TI mutants (TAp63a
FTL4AAA, TAp63a
TIS4AAA)
project directly onto this conserved 10-amino-acid sequence
(Figure 3). The mutagenesis data, supported by sequence
alignments, thus deﬁne the core of the TI domain as the 10-
amino-acid stretch from R604 to F613 (RFTLRQTISF), with
some less conserved C-terminal ﬂanking regions (PPR in
human p63) as additionally functionally important.
The results reported above provide further evidence that the
TID contains two independent regulatory functions, of which
one is based on sumoylation in the C-terminus of the TID and
theotherpresumablyonbindingandmaskingoftheTAdomain,
and each of these being responsible for approximately 50% of
the observed inhibition within TAp63a. The separate nature of
these two functions is further demonstrated by sequence
comparison of the TI domains of vertebrates and invertebrates
(Figure3):Inadditiontotheaminoacidsconstitutingthecoreof
the TID, the IKEE sumoylation site at the C-terminus is highly
conserved in vertebrate sequences. Surprisingly, however, the
sumoylation site is missing in invertebrate sequences. Further
sequence analysis revealed an (I/V)KEE sequence N-terminal
to the SAM domain in all sequences that miss the C-terminal
sumoylation site. Investigation of the corresponding TAp63a
protein of Mytilus trossulus (mt-TAp63a) suggested that the
elements that control the transcriptional activity in mammalian
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Figure 2 (a) The measurement of the transcriptional activity as shown in
Figure 1 was repeated with all triple alanine mutants carrying an additional K637L
mutation to remove the sumoylation site. Each measurement was carried out in
triplicate. (b) The intracellular protein level was determined by western blot analysis
of p63 and normalized using western blots of GAPDH. The transcriptional activity of
thedifferentmutantswasthennormalizedforintracellularconcentration.Theresults
are very similar to those obtained in the series with an intact sumoylation site
(Figure 1), which suggests that the sumoylation is not directly involved in controlling
the activity of p63, but acts indirectly by inﬂuencing the intracellular concentration
Figure 3 Sequence alignment of C-terminal p63 sequences of various vertebrate and invertebrate species. Sequences N-terminal to the SAM domain to the end of the
protein are shown. The sequences of the SAM domains themselves are not shown. Strictly conserved amino acids are labeled red. The conserved KEE sumoylation motif is
labeled in blue. This sumoylation sequence is located N-terminal to the SAM domain in invertebrate species
p63a C-terminal mutational analysis
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Cell Death and DiseaseTAp63a are indeed conserved in this invertebrate protein
(Supplementary Figure S2).
Sumoylation regulates the intracellular concentration.
Sumoylation can have different effects on proteins and can
inﬂuence stabilization, destabilization, or intracellular locali-
zation.
21–25 In the case of p63, sumoylation has been reported
to destabilize the protein.
18 To investigate whether the
increase in transcriptional activity of the p63 mutants with a
mutated sumoylation site might reﬂect changes in concen-
tration rather than release of an inhibitory effect, we
determined the concentration of the different p63 mutant
forms in the lysates of the samples tested for transcriptional
activity by western blotting. Most alanine scanning mutants
showed a high abundance similar to wild-type TAp63a.
Only mutations in the conserved 10-amino-acid stretch
and in the sumoylation site signiﬁcantly altered the observed
protein concentration. The two mutants TAp63a
FTL4AAA and
TAp63a
TIS4AAA, and TAp63a
PPR4AAA, a mutant directly
C-terminal to the conserved stretch, decreased in concentra-
tion, whereas the sumoylation mutant TAp63a
QRI4AAA
increased in concentration (Figure 1a). This observation is
consistent with earlier investigations that had revealed that
transcriptionally active TAp63g shows a signiﬁcantly reduced
intracellular concentration compared with transcriptionally
impaired mutants.
26
As further analysis, the concentrations of TAp63a were
quantiﬁedbydensitometrytoproduceaproteinconcentration-
based normalization factor for the transcriptional activity of
each clone. The activity data for the experimental series with
both mutant libraries were re-processed with these normal-
ization factors, thus removing a concentration-dependent
inﬂuence on the measured activity (Figures 1b and 2b,
Supplementary Figures S3 and S4). For TAp63a the activity
increase observed with disruption of the sumoylation site was
directly proportional to the increase in protein concentration,
resulting in no net increase in activity. Normalization of the
activities for all mutants in both series produced similar
results, showing thatmutationsin a stretch between F605and
R616 led to signiﬁcantly increased transcriptional activity that
reaches B70% of the activity of TAp63g. In contrast, the
activity for all other mutants remained low, with some showing
a slight increase relative to the activity of wild-type TAp63a.
Sumoylation, therefore, affects the intracellular protein con-
centration, but does not decrease the intrinsic transactivation
potential of wild-type TAp63a or truly ‘inhibit’ the transcription
factor.
As a control experiment to investigate the relationship
between sumoylation and intracellular protein concentration,
we used siRNAs to knock down the SUMO-E2 enzyme Ubc9.
This protein is a key enzyme for sumoylation reactions
27–29
and knockdown of Ubc9 was shown to abolish sumoylation of
p63.
17 Knockdown of Ubc9 using siRNAs led to an increase in
the transcriptional activity of TAp63a by 60% as compared
with cells transfected with mock siRNAs (Supplementary
Figure S5). No effect could be observed with TAp63g.
Western blot analysis conﬁrmed that the increase in the
transcriptional activity of TAp63a was proportional to an
increase in the intracellular concentration of the protein. After
normalization with respect to protein concentration, both
siRNA- and mock siRNA-treated cells showed nearly the
same transcriptional activity (Supplementary Figure S5). The
effect of knocking down Ubc9 on the p63 concentration and
activity was less than the effect of mutating the SUMO
acceptor site. This difference can be explained with the only
partial knockdown of Ubc9 (approximately 70%). Never-
theless, the overall trend of these experiments conﬁrms our
interpretation that sumoylation inﬂuences the intracellular
concentration.
The amino acids of the TI core are solely responsible for
a sequence-speciﬁc intramolecular interaction. Previous
experiments had suggested that the last 25 amino acids of
the TI domain, containing the sumoylation site, are not
involved in binding and masking of the TA domain.
15
Contribution to binding had been evaluated by pulldown
assays with an external GST–TID fusion protein. In this
assay, isoforms with an unmasked TA domain bind to this
external TID. The TA domain of wild-type TAp63a possesses
an intact intramolecular interaction with its TI domain and
therefore does not bind efﬁciently to the external GST–TID
(Figure 4). TAp63g, in contrast, possesses an available TA
domain with which it binds efﬁciently to the GST–TID resin.
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Figure 4 Pulldown assays of different p63 forms with GST–TID fusion protein
bound to a glutathione column. An antibody against the N-terminal myc-tag of the
constructs was used for the experiments. (a) Raw data with the ﬁrst lane showing
theamountofproteinusedforthepulldownexperiments,secondlanetheamountof
protein boundto the column and third lane theamount of protein bound to a column
loaded with a mutated form of the GST–TID fusion protein (GST–TID
mut (F605A/
T606A/L607A/T610A/I611A/S612A)). The ﬁrst lane on the left of the graph shows a
molecular weight marker. (b) Quantitative analysis of the pulldown experiments
shownin(a).TAp63gandTAp63amutantswithamutatedTIdomainthatshowhigh
transcriptional activity are bound efﬁciently to the GST–TID fusion protein. TAp63a
mutants that are not transcriptionally active do not bind to the external TI domain.
Pulldown experiments with a mutated TID fused to GST do not result in detectable
amounts of protein. Each experiment was carried out in triplicate
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Cell Death and DiseaseMutation of the sumoylation site (TAp63a
K637L) did not affect
the amount of protein bound. The intramolecular interaction
of TAp63a
K637L therefore remained intact and the amino
acids that constitute the sumoylation site do not contribute to
the intramolecular interaction. TAp63a
SVG4AAA,a sa n
additional negative control, also bound to the GST–TID
resin with an efﬁciency similar to TAp63a
wt. Mutation of
amino acids in the core TI domain (TAp63a
FTL4AAA and
TAp63a
TIS4AAA) led to a 5–6-fold increase of protein bound
to the resin, which is a result comparable to TAp63g.A sa n
additional control to demonstrate that the interaction between
GST–TID and TAp63g, TAp63a
FTL4AAA and TAp63a
TIS4AAA
is sequence speciﬁc, the pulldown assays were also
performed with a mutated version of the TID, GST–TID
mut
(F605A/T606A/L607A/T610A/I611A/S612A) (Figure 4). The
amount of protein bound to GST–TID
mut was undetectable in
all samples and thus conﬁrmed that the C-terminal sequence
between A602 and S612 of TAP63a is responsible for the
intramolecular interaction.
Mutations in the core of the TI domain affect the
dominant-negative behavior of DNp63a. The initial
characterization of the transcriptional activity of the different
p63 isoforms had revealed that DNp63a shows a strong
dominant-negative behavior towards TAp63g on the p21
promoter in SAOS2 cells.
2 As DNp63g is only weakly
dominant negative and in low concentrations even
enhances the transcriptional activity of TAp63g, the
inhibitory function of DNp63a could be assigned to the C-
terminus of the a-isoform. Although the biological relevance
of this dominant-negative behavior is currently not clear, this
effect provides another interesting assay to further
investigate the behavior of mutations in the TI domain. We,
therefore, created a mutant of DNp63a with the TA-binding
site mutated (DNp63a
FTL4AAA) and tested this mutant in
titration assays against TAp63g. The plasmid DNAs for
DNp63a constructs were mixed with TAp63g at ratios of 1:4,
1:2, 1:1, 2:1 and 4:1, transfected into SAOS-2 cells, and
assayed on the p21 promoter. The transcriptional activity
was normalized with the help of western blot analysis. As
reliable western blot signals could be obtained only for
concentrations of the DN forms above a ratio of 1:1, only
these data are shown in Figure 5. The unnormalized raw data
and the corresponding western blots are shown in
Supplementary Figure S6.
Wild-type DNp63a potently inhibited TAp63g, and at a
plasmid ratio of 1:2 (DNp63a:TAp63g) over 90% of the
activity was removed. Mutation of the TID (DNp63a
FTL4AAA)
resulted in a slightly reduced ability to inhibit the transcrip-
tional activity of TAp63g, reaching approximately 10% activity
at the highest expression level of DNp63a
FTL4AAA. Separate
investigation of the transcriptional activities of DNp63a and
DNp63a
FTL4AAA on the p21 promoter in SAOS2 cells showed
that both are transcriptionally inactive (Supplementary Figure
S7; it should, however, also be mentioned that DNp63a has
been shown to be transcriptionally active on other promoters).
As both DN forms accumulate to much higher intracellular
levels than TAp63g, the inhibitory effect of both proteins could
at least in part be due to competition for promoter binding
sites.Todistinguishbetweenthedirectinhibitionthroughthea
C-terminus and the indirect inhibition through competition for
DNA binding sites, we repeated these experiments with DNA-
bindingdomainmutantsofbothDNforms(Figure5).Whereas
the DNA-binding mutant of DNp63a still resulted in approxi-
mately 90% inhibition of the TAp63g activity, the inhibitory
potential of the DNA-binding mutant of DNp63a
FTL4AAA was
signiﬁcantly reduced, levelling off at 50% transcriptional
activity at the highest protein level. These results showed
that the inhibitory effect of DNp63a is to a large extent due to
the a C-terminus and mutation of the FTL stretch signiﬁcantly
reduces the inhibitory effect of the TID. Still 50% inhibitory
potential of the DNA-binding mutant of DNp63a
FTL4AAA
remained. However, at high protein levels of DNp63a
FTL4AAA
most of the TAp63g will form mixed tetramers with
DNp63a
FTL4AAA. As dimers are formed co-translationally,
30
most likely the dominant form is a hetero-tetramer consisting
of TAp63g and DNp63a
FTL4AAA homo-dimers. Owing to the
DNA-binding mutation of DNp63a
FTL4AAA, the mixed tetra-
mers effectively behave as dimers. Mutation of the tetramer-
ization domain creating TAp63g dimers results in 50%
transcriptional activity (Supplementary Figure S8). Interest-
ingly, a similar 50% decrease in transcriptional activity was
reported for p53 dimers.
31
Discussion
Two of the six p63 isoforms contain an extended C-terminus
with two distinct regulatory elements that combine to auto-
inhibit TAp63a and impart a dominant-negative ability to
DNp63a. Although the biological relevance of the dominant-
negative function of DNp63a towards TAp63g is unclear, the
recent discovery that TAp63a has a major role in protecting
the female germ line
12 suggests a clear biological function of
the TID for TAp63a. During oogenesis cells arrest in the
prophase of meiosis I (dictyate arrest) until they are recruited
for ovulation. This period, which can last up to several
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Figure 5 Inhibition of the transcriptional activity of TAp63g by increasing
amounts of different DNp63a mutants. The relative amount of the DNp63a forms
wasvariedfrom4:1(TAp63g:DNp63a)to1:4.Theratiosareshownonthex-axis.
Theleftmostpointcorrespondsto thetranscriptional activityof TAp63galone,which
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T606A/L607A); dNp63alpha.DBD: DNp63a mutant R279H incapable of binding to
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transcriptional activity was normalized relative to the intracellular concentration of
DNp63a with the help of western blot analysis. Each measurement was carried out
in triplicate
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Cell Death and Diseasedecades in humans, is characterized by strong expression of
TAp63a in the arrested cells. Experiments with mice showed
that in these arrested oocytes TAp63a is transcriptionally
inhibited. The binding afﬁnity to DNA increased B20-fold upon
exposure to ionizing radiation, which was accompanied by p63
phosphorylation and death of the oocytes. Combining these
mouse studies with our biochemical investigation of the TID
suggests that TAp63a is kept in a transcriptionally inhibited
conformation by the TID. Essential for keeping the protein in
this conformation is a short stretch of highly conserved amino
acids that inhibits the transcriptional activity of TAp63a by
directly binding to other p63 domains. The existence of several
highly conserved threonines and serines in the TID suggests
that phosphorylation might be a possible mechanism of relief
of inhibition. A simple mutation of threonine 606 to gluta-
mate, however, did not result in a signiﬁcant increase in
the transcriptional activity of TAp63a, showing either that this
mutation is not a good mimetic of phosphorylation or that the
activation mechanism is more complex. Obviously, to answer
this question, the identiﬁcation of kinases that phosphorylate
the C-terminus of p63 would be essential.
In our previous investigation, we had shown direct interac-
tion between the bacterially expressed TA and the TI
domains, suggesting a masking of the transactivation domain
as the basis for transcriptional inhibition.
15 The data reported
by McKeon and colleagues
12 show that phosphorylation
increases the DNA-binding afﬁnity, suggesting that transcrip-
tional repression might be caused by inhibiting several
functions of the molecule. Such a multiple inhibitory mechan-
ism could be realized by forming a closed conformation of the
protein inwhich – in addition tothe TA–TI interaction – several
other domain–domain interactions occur.
Our investigation has revealed that the TI domain harbors a
second inhibitory function, which is based on sumoylation of
K637. Sumoylation, however, does not seem to be directly
involved in suppressing the intrinsic transcriptional activity of
p63, but acts indirectly by controlling the intracellular level.
Several investigations have shown that endogenous DNp63a
becomes sumoylated in several different cell lines and if
transfected in SAOS2 cells.
18 Furthermore, direct interaction
of TAp63a and DNp63a with Ubc9 was demonstrated in
transiently transfected human embryonic retina 911 cells.
17
Association between p63 and SUMO-1 could be completely
abolishedbyaK637Emutationandthesamemutationledtoa
dramatic increase in the transactivation of TAp63a on the
RGC promoter. Similar to p63, sumoylation has also been
observed for the highly homologous protein p73 and it was
shown that sumoylation regulates the intracellular concentra-
tion.
19 All together, these different investigations by different
research groups using different cell lines and promoters
strongly suggest that sumoylation is involved in regulating the
activity of p63. Our new study shows that at least in SAOS2
cells the inﬂuence of sumoylation on the transcriptional
activity is due to regulation of the intracellular concentration
while the inhibitory effect of the TID that is based on direct
binding is not affected.
Our current and previous studies highlight an interesting
correlation between high transcriptional activity and low
intracellular concentration, which has also been observed
by others.
26 This observation suggests that additional
mechanisms exist to decrease the concentration of transcrip-
tionally active forms without affecting transcriptionally re-
pressedforms.Theexistenceofsuchdifferentmechanismsis
further supported by the observation that the concentration of
the transcriptionally active forms TAp63a
FTL/IKEE4AAA/ILEE
and TAp63a
FTL4AAA that are barely detectable in western
blots strongly increases when they are rendered transcrip-
tionally inactive by an additional mutation in the DNA-binding
domain (Figure 6). These results also suggest that the
formation of a transcriptionally active complex on the DNA is
important for the degradation of p63. It is tempting to
speculate that the intracellular concentration of transcription-
allyinactiveformsismainlyregulatedbysumoylationwhereas
that of transcriptionally active forms is dominated by
ubiquitination by Itch, MDM2 or other E3 ligases that have
been shown to interact with p63.
32–38 Differences in the
mechanism of degradation between transcriptionally inactive
and active forms have been observed for other proteins such
as the estrogen receptor hERa as well.
39
Although no point mutations in the core of the TID have
been identiﬁed to date in human syndromes, mutationsjust N-
terminal to this stretch (R598L, D601V) in patients with AEC
syndrome have been reported.
40 In addition, patients with
split-hand split-foot malformation type 4 who have nonsense
mutations that create protein forms truncated by only a few
amino acids (eight in Q634X and three in E639X) have been
described,
41 which leads to the destruction of the sumoylation
site. Several explanations for the surprising absence of
missense mutations in the core of the TID exist. First, such
mutations could be lethal. Second, a syndrome would arise
only if the mutations would create either a dominant-negative
or a gain-of-function effect. If the main effect of mutations in
the TID is a loss of the dominant-negative behavior toward
other transcriptionally active forms, expression from the
second, non-mutated allele might be enough to sustain the
biological function of DNp63a during development and
maintenance of epithelial tissue. Finally, it is also possible
that transcriptional inhibition is only important for TAp63a,
which monitors the genetic stability of oocytes, and not for
DNp63a’s role in maintaining epithelial stem cells. The effect
of mutations on p63’s role in oocyte quality control, however,
has just begun to be investigated.
Materials and Methods
Plasmids. The mammalian expression vectors encoding N-terminally tagged
TAp63a, DNp63a, and TAp63g in pCDNA3.1 and the pGL3 vector were obtained
from Frank McKeon (Department of Cell Biology, Harvard University). The fusion of
TAp63α
FTL
FTL.K
FTL.DBD
FTL.K.DBD
GAPDH
p63
Figure 6 Comparison of the intracellular concentrations of the active triple-
alanine mutants TAp63a
FTL4AAA and TAp63a
FTL/IKEE4AAA/ILEE with the concen-
trations of their corresponding DBD mutants. TAp63a is shown as a control. Each
measurement was carried out in triplicate
p63a C-terminal mutational analysis
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Mu ¨nchen, Germany) has been described earlier.
15 All mutants were generated using
the Quickchange site-directed mutagenesis protocol. The second-generation library,
clones18–32,wasgeneratedbyaddingtheK637Lmutationtoclones1–16(Table1).
Transactivation assays. All transactivation experiments were performed in
SAOS-2 cells using the Promega (Mannheim, Germany) Dual-Glo Luciferase
reporterassay.Forthetransfectionassays,aconstructwithasinglecopyofthep21
promoter obtained from human genomic DNA was cloned into the pGL3 vector.
Cells were obtained from the ATCC and maintained in Dulbecco’s modiﬁed Eagle’s
medium with 10% fetal bovine serum at 371C under an atmosphere of 5% CO2.
Cells were transfected with 133ng DNA per plasmid (Effectene, Qiagen, Hilden,
Germany) in 96-well plates, grown for 24h and assayed for Renilla and Fireﬂy
luciferase activities. For titration assays, the concentration of TAp63g was kept
constant at 66ng per assay and the amount of DNp63a plasmid was varied from a
ratio of 1:4 to 4:1. The total amount of DNA transfected was kept constant with
empty pCDNA3.1. The transcriptional activity was normalized with the help of
western blots analysis. As reliable western blot signals could be obtained only for
concentrations of the DN forms above a ratio of 1:1, only these data are shown in
the unnormalized raw data and the corresponding western blots are shown in
Supplementary Figure S6. A total of three independent experiments were
performed, each in triplicate. The linear relationship between intracellular protein
concentration and transcriptional activity, which was important for normalization of
the transcriptional activity, was tested by comparing the transcriptional activity and
concentration obtained with the plasmid amount used in the experiments with the
results from experiments with half or twice the amount of plasmid transfected. For
both TAp63a and TAp63a
FTL4AAA, these tests showed a linear relationship
between the amount of plasmid, the intracellular concentration, and the
transcriptional activity (Supplementary Figure S9). Error margins are given as the
normalized difference between the maximum value and the average value. In the
case of the concentration-normalized transcriptional activities, the error resulting
from the determination of the concentration was added to the error obtained from
the determination of the transcriptional activity, weighted by the ratio of normalized
activity and relative activity.
Immunohistochemistry using an anti-myc antibody coupled to a Cy3-ﬂuorophore
(Sigma, Hamburg, Germany) showed that all mutants tested, as well as wild-type
TAp63a and TAp63g, were exclusively nuclear (Supplementary Figure S10).
Western blotting analysis. As further analysis, the concentrations of
TAp63a and GAPDH were quantiﬁed by densitometry to produce a protein
concentration-based normalization factor for the transcriptional activity of each
clone. Normalizing this concentration-based normalization factor for transfection
efﬁciency using the Renilla data led to the identiﬁcation of the exactly same stretch
of amino acids, albeit with different intensities as compared with Figures 1b and 2b.
The activity data for the experimental series with both mutant libraries were re-
processed with these normalization factors, thus removing a concentration-
dependent inﬂuence on the measured activity (Figures 1b and 2b, Supplementary
Figures S3 and S4). SAOS-2 cells were transfected in the same manner as for the
transactivationassayswithdifferentp63-containingpCDNA3.1plasmids(Effectene,
Qiagen). Cells were harvested after 24h, resuspended, and lysed in M-PER
reagent (Pierce, Schwerte, Germany) for 5min. After addition of 15mlo f4 SDS
buffer containing 20% b-mercaptoethanol, samples were heated for 5min at 951C.
A volume of 7ml of the lysate was loaded onto a 17-well NuPage (Invitrogen,
Karlsruhe, Germany) 4–12% Bis–Tris (SDS) polyacrylamide gel. Samples were
transferred to a PVDF membrane (Immobilon-P 0.45mM) (Millipore, Schwalbach,
Germany) using an XCell II blot module. The blot was blocked in 5% skim milk and
probed with mouse anti-myc antibody clone 4A6 (Millipore), anti-ubc-9 rabbit
polyclonalantibody(CellSignaling,Frankfurt,Germany),oranti-GAPDH(Chemicon
International). Detection was performed using an HRP goat anti-mouse IgG
peroxide conjugate (Sigma). The blots were quantitated using the Biometra
BioDocAnalyze 2.0 software (Biometra, Go ¨ttingen, Germany). Each experiment
was repeated three times.
siRNA experiments. SAOS2 cells were transfected either with siRNA
targeting Ubc9 or with siRNA with a randomized sequence as a control
experiment. The following sequence was used to target Ubc-9 (reference
sequence: NM_003345) 50-AAGGGATTGGTTTGGCAAGAA-30. The unmodiﬁed
siRNAs were purchased from Qiagen and transfected using RNAifect transfection
reagent (Qiagen) at a ﬁnal concentration of 60nM following the manufacturer’s
instructions. At 24h after siRNA transfection, cells were transfected with p63-coding
plasmidsasmentionedbefore.Cellswereharvestedafter24h and thetranscriptional
activity and protein concentration were determined as described above.
Protein–protein interaction assays. All TI domain mutants described
above were expressed in an in vitro rabbit reticulate lysate transcription/translation
system and pulldown experiments were performed using a bacterially expressed
and puriﬁed E. coli GST–TID fusion protein bound to a glutathione-based afﬁnity
resin. The GST fusion protein system (GE Healthcare) was used to detect protein–
protein interactions between p63 proteins and immobilized domains. The GST–TID
protein used as bait was made by cloning p63 amino acids 569–616 into the pGEX-
6p-2 vector. An additional His-tag was added at the C-terminus. The GST–TID
proteinwasexpressedinBL21(DE3)cells.Theexpressedproteinwaspuriﬁedover
a10-mlNi-IDAFastFlowcolumnusingagradientfrom50to400mMimidazole.The
eluent was diluted with 30% glycerol, aliquoted into 1ml fractions and frozen at
 801Cforlateruseataconcentrationofapproximately0.5mg/ml.Pulldownassays
wereperformedincentrifugalﬁltrationunitsusingaDuraporemembranewithapore
size of 0.65mm (Millipore UFC30DV00) and a table top centrifuge operating at
1000r.p.m.Inall,250mloftheGST–TIDproteinwasincubatedfor15minwith50ml
of Glutathione resin pre-equilibrated in Pull-Down Buffer A (180mM NaCl, 0.1%
Tween-20,50mMTrispH8.0).Theresinwaswashedfourtimeswith400mlof Pull-
Down Buffer A to remove excess GST–TID. Thep63 proteins used as inputs for the
assay were generated in an in vitro transcription/translation rabbit reticulate lysate
system (Promega) with 1mg of template DNA. A volume of 5ml of the reaction
mixturewasremovedforuseasaninputcontrol.Theremaining55mlwasincubated
withtheGST–TIDresinfor3hat41Candthencentrifuged.Theresinwaswashed4
times with 400ml of Pull-Down Buffer A and the bound proteins were eluted with
2 20mlo f2  hot SDS-PAGE buffer. Analysis after SDS-PAGE was performed
by western blotting as described above.
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